Bill fails to recognize business model of generic industry.
WASHINGTON, DC (October 10, 2017) – State laws that burden manufacturers of low-cost generic and biosimilar medicines harm patients and decrease competition with expensive brand name drugs. The California bill fails to recognize that the business model of the generic industry, in which low-cost medicines can fluctuate in price while continuing to decline overall, is vastly different from brand drugs. Patients are well-served by legislative approaches, which acknowledge the differences between brands and generics and which facilitate, not chill, generic competition.
Attribution: Jeffrey K. Francer, Senior Vice President and General Counsel